Global Erectile Dysfunction Drugs Market

Erectile Dysfunction Drugs Market Size, Share, Growth Analysis, By Mode of Administration(Oral Medications, Topical Medications, Injections, and Others), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Sales, and Others.), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35I2259 | Region: Global | Published Date: February, 2024
Pages: 157 |Tables: 65 |Figures: 75

Erectile Dysfunction Drugs Market Insights

Global Erectile Dysfunction Drugs Market size was valued at USD 2.3 Billion in 2021 and is poised to grow from USD 2.50 Billion in 2022 to USD 4.79 Billion by 2030, at a CAGR of 8.5% during the forecast period (2023-2030).

The high prevalence of sedentary lifestyles and lifestyle diseases, including obesity, cardiovascular diseases, diabetes, and high blood pressure, are key contributors to the increased demand for erectile dysfunction drugs in the global market. The growing geriatric population, coupled with rising patient awareness and education levels, is also driving market growth. Government reforms and public awareness initiatives in developing regions are further fuelling market expansion. The availability of generic drugs, along with the sedentary lifestyle and associated stress, is boosting market growth. Additionally, the increasing number of men suffering from erectile dysfunction and the patent expiry of several blockbuster drugs are significant factors driving market growth. Investments in research and development (R&D) and clinical trials for new drug development are creating additional growth opportunities. However, challenges such as poor patient adherence, availability of cost-effective counterfeit drugs, and potential side effects may hinder market growth.

Market Snapshot - 2024-2031

Global Market Size

USD 2.3 Billion

Largest Segment

Hospital Pharmacies

Fastest Growth

Hospital Pharmacies

Growth Rate

8.5% CAGR

Global Erectile Dysfunction Drugs Market ($ Bn)
Country Share for North America Region (%)

To get more reports on the above market click here to Buy The Report

Erectile Dysfunction Drugs Market Segmental Analysis

The global erectile dysfunction drugs market is segmented on the basis of mode of administration, distribution channel, and region. By mode of administration, the market is segmented into oral medications, topical medications, injections, and others. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online sales and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Analysis By Mode of Administration

The dominant mode of administration for erectile dysfunction drugs, accounting for the largest market share. This is due to the fact that oral medications are convenient and easy to use.

The fastest-growing mode of administration for erectile dysfunction drugs, accounting for a moderate market share in 2022. This is due to the fact that topical medications are convenient and easy to use, and they have fewer side effects than oral medications. The dominant mode of administration for erectile dysfunction drugs is oral medication, followed by injectable medication and topical medication. The fastest-growing mode of administration is topical medication.

Analysis By Distribution Channel

Hospital pharmacies are the dominant distribution channel for erectile dysfunction drugs, accounting for the largest market share. This is due to the fact that hospital pharmacies are the primary source of prescription medications for erectile dysfunction drugs.

Online pharmacies are the fastest-growing distribution channel for erectile dysfunction drugs, accounting for a moderate market share. This is due to the increasing popularity of online shopping and the convenience of ordering erectile dysfunction drugs online.

Global Erectile Dysfunction Drugs Market By Distribution Channel, 2023 (%)

To get detailed analysis on other segments, Request For Free Sample Report

Erectile Dysfunction Drugs Market Regional Insights

North America is the dominant region in the global erectile dysfunction drugs market, accounting for the largest market share in 2022. This is due to the fact that North America has a high prevalence of erectile dysfunction, a strong healthcare infrastructure, and a large number of patients who are willing to pay for erectile dysfunction drugs.

Asia Pacific is the fastest-growing region in the global erectile dysfunction drugs market, accounting for a moderate market share in 2022. This is due to the fact that Asia Pacific has a growing middle class, an increasing awareness of erectile dysfunction, and a growing number of patients who are willing to pay for erectile dysfunction drugs.

Global Erectile Dysfunction Drugs Market By Region, 2024-2031
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Erectile Dysfunction Drugs Market Dynamics

Drivers

Increasing Prevalence of Erectile Dysfunction

  • The rising prevalence of erectile dysfunction globally is a major driver for the market. Factors such as sedentary lifestyles, obesity, chronic diseases (diabetes, cardiovascular diseases), and aging contribute to the growing incidence of erectile dysfunction.

Growing Aging Population

  • The global population is aging, and older individuals are more prone to erectile dysfunction. The increasing elderly population drives the demand for erectile dysfunction drugs.

Restraints

Regulatory Challenges

  • Regulatory requirements and approvals for erectile dysfunction drugs can be time-consuming and costly. Stringent regulations, including clinical trial requirements and post-marketing surveillance, pose challenges for manufacturers and slow down product launches, impacting market growth.

Availability of Non-pharmaceutical Alternatives

  • Non-pharmaceutical alternatives such as lifestyle modifications, psychotherapy, and vacuum erection devices are available for managing erectile dysfunction. Some individuals may prefer these alternatives, which could limit the demand for erectile dysfunction drugs.

Request Free Customization of this report to help us to meet your business objectives.

Erectile Dysfunction Drugs Market Competitive Landscape

The competitive landscape of the global erectile dysfunction drugs market is characterized by intense competition and a range of players striving to capture a significant market share. The market is highly dynamic, with multiple pharmaceutical companies and manufacturers vying to provide effective treatment options for erectile dysfunction. These players focus on research and development activities to develop innovative drugs and enhance existing formulations. Strategic alliances, collaborations, and partnerships with healthcare providers, research institutions, and distribution networks are common strategies employed to gain a competitive edge. Additionally, marketing initiatives, brand building, and extensive product promotion are crucial for market penetration and creating awareness among target consumers. The competitive landscape is further influenced by factors such as patent protections, regulatory approvals, pricing strategies, and the ability to address safety concerns associated with these drugs. The presence of generic alternatives also impacts competition and market dynamics. Overall, the global erectile dysfunction drugs market presents a competitive environment driven by innovation, strategic partnerships, and effective marketing strategies.

Top Player’s Company Profile

  • Johnson & Johnson - United States
  • GSK (GlaxoSmithKline) - United Kingdom
  • Novartis International AG - Switzerland
  • Sanofi - France
  • AstraZeneca - United Kingdom
  • Boehringer Ingelheim - Germany
  • Teva Pharmaceutical Industries Ltd. - Israel
  • Mylan N.V. - United States
  • Endo International plc - Ireland
  • Amgen Inc. - United States
  • Bristol Myers Squibb - United States
  • AbbVie Inc. - United States
  • Actavis (now part of Teva Pharmaceutical Industries) - United States
  • GlaxoSmithKline Consumer Healthcare Ltd. - United Kingdom
  • Sun Pharmaceutical Industries Ltd. - India
  • Torrent Pharmaceuticals Ltd. - India
  • Cadila Healthcare Ltd. - India

Recent Developments

  • March 2022: The US FDA permitted Lupin to commercialize a generic version of Revatio from Viatris Specialty LLC. Lupin's ANDA for sildenafil (10 mg/mL oral suspension) gained this approval.
  • January 2023: Petros Pharmaceuticals, Inc., initiated two self-selection studies for its erectile dysfunction (ED) drug STENDRA (avanafil).
  • February 2023: Astellas Pharma announced the launch of Vyleesi (bremelanotide) in the United States. Vyleesi is a new injectable medication for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

Erectile Dysfunction Drugs Key Market Trends

  • Rising Demand for Non-Oral Administration Routes: While oral medications (such as PDE5 inhibitors) have been the primary treatment option for erectile dysfunction, there is an increasing demand for alternative administration routes. This includes the development of topical creams, injections, and transdermal patches that offer localized and targeted treatment.
  • Emergence of Novel Therapies: The market is witnessing the emergence of novel therapies beyond traditional pharmaceutical drugs. These include shockwave therapy, penile implants, vacuum erection devices, and regenerative medicine approaches using stem cells or platelet-rich plasma (PRP). These innovative treatments provide additional options for patients and contribute to market growth.

Erectile Dysfunction Drugs Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.

According to our global erectile dysfunction drugs market analysis, the increasing prevalence of erectile dysfunction, growing aging population, rising awareness, and advancements in treatment options are the key growth drivers. The market is witnessing a shift towards personalized medicine and the development of non-oral administration routes, offering patients more tailored and convenient treatment choices. Additionally, the emergence of novel therapies beyond pharmaceutical drugs, such as shockwave therapy and regenerative medicine, is expanding the treatment landscape. Online sales channels and direct-to-consumer marketing are also gaining prominence.

In terms of regional dominance, North America is currently the leading market for erectile dysfunction drugs due to factors like high awareness, advanced healthcare infrastructure, and a large patient pool. Europe also holds a significant market share, driven by favourable reimbursement policies and increasing demand for effective treatments. Asia Pacific is the fastest-growing region in the global erectile dysfunction drugs market, primarily attributed to the rising prevalence of erectile dysfunction, expanding healthcare access, and increasing healthcare expenditure in countries like China and India. Additionally, initiatives to improve healthcare infrastructure and growing patient awareness are contributing to the region's growth. Overall, the global erectile dysfunction drugs market is expected to continue its upward trajectory, supported by ongoing research and development activities, strategic collaborations, and the introduction of innovative therapies. However, challenges such as safety concerns, patent expirations, and the availability of non-pharmaceutical alternatives remain as potential obstacles to market expansion.

Report Metric Details
Market size value in 2023 USD 2.3 Billion
Market size value in 2031 USD 4.79 Billion
Growth Rate 8.5%
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Mode of Administration
    • Oral Medications, Topical Medications, Injections, and Others
  • Distribution Channel
    • Hospital Pharmacies, Retail Pharmacies, Online Sales, and Others.
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Johnson & Johnson - United States
  • GSK (GlaxoSmithKline) - United Kingdom
  • Novartis International AG - Switzerland
  • Sanofi - France
  • AstraZeneca - United Kingdom
  • Boehringer Ingelheim - Germany
  • Teva Pharmaceutical Industries Ltd. - Israel
  • Mylan N.V. - United States
  • Endo International plc - Ireland
  • Amgen Inc. - United States
  • Bristol Myers Squibb - United States
  • AbbVie Inc. - United States
  • Actavis (now part of Teva Pharmaceutical Industries) - United States
  • GlaxoSmithKline Consumer Healthcare Ltd. - United Kingdom
  • Sun Pharmaceutical Industries Ltd. - India
  • Torrent Pharmaceuticals Ltd. - India
  • Cadila Healthcare Ltd. - India
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Erectile Dysfunction Drugs Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Erectile Dysfunction Drugs Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Erectile Dysfunction Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Erectile Dysfunction Drugs Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Erectile Dysfunction Drugs Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Erectile Dysfunction Drugs Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Erectile Dysfunction Drugs Market size was valued at USD 2.3 Billion in 2021 and is poised to grow from USD 2.50 Billion in 2022 to USD 4.79 Billion by 2030, at a CAGR of 8.5% during the forecast period (2023-2030).

The competitive landscape of the erectile dysfunction drugs market is characterized by intense competition and a range of players striving to capture a significant market share. The market is highly dynamic, with multiple pharmaceutical companies and manufacturers vying to provide effective treatment options for erectile dysfunction. These players focus on research and development activities to develop innovative drugs and enhance existing formulations. Strategic alliances, collaborations, and partnerships with healthcare providers, research institutions, and distribution networks are common strategies employed to gain a competitive edge. Additionally, marketing initiatives, brand building, and extensive product promotion are crucial for market penetration and creating awareness among target consumers. The competitive landscape is further influenced by factors such as patent protections, regulatory approvals, pricing strategies, and the ability to address safety concerns associated with these drugs. The presence of generic alternatives also impacts competition and market dynamics. Overall, the erectile dysfunction drugs market presents a competitive environment driven by innovation, strategic partnerships, and effective marketing strategies. 'Pfizer Inc. - United States', 'Eli Lilly and Company - United States', 'Bayer AG - Germany', 'Johnson & Johnson - United States', 'GSK (GlaxoSmithKline) - United Kingdom', 'Novartis International AG - Switzerland', 'Sanofi - France', 'AstraZeneca - United Kingdom', 'Boehringer Ingelheim - Germany', 'Teva Pharmaceutical Industries Ltd. - Israel', 'Mylan N.V. - United States', 'Endo International plc - Ireland', 'Amgen Inc. - United States', 'Bristol Myers Squibb - United States', 'AbbVie Inc. - United States', 'Actavis (now part of Teva Pharmaceutical Industries) - United States', 'GlaxoSmithKline Consumer Healthcare Ltd. - United Kingdom', 'Sun Pharmaceutical Industries Ltd. - India', 'Torrent Pharmaceuticals Ltd. - India', 'Cadila Healthcare Ltd. - India'

The rising prevalence of erectile dysfunction globally is a major driver for the market. Factors such as sedentary lifestyles, obesity, chronic diseases (diabetes, cardiovascular diseases), and aging contribute to the growing incidence of erectile dysfunction.

Rising Demand for Non-Oral Administration Routes: While oral medications (such as PDE5 inhibitors) have been the primary treatment option for erectile dysfunction, there is an increasing demand for alternative administration routes. This includes the development of topical creams, injections, and transdermal patches that offer localized and targeted treatment.

North America is the dominant region in the erectile dysfunction drugs market, accounting for the largest market share in 2022. This is due to the fact that North America has a high prevalence of erectile dysfunction, a strong healthcare infrastructure, and a large number of patients who are willing to pay for erectile dysfunction drugs.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Erectile Dysfunction Drugs Market

Product ID: SQMIG35I2259

$5,300
BUY NOW GET FREE SAMPLE